The administration of a diarylsulfonylurea, LY186641, which is presently undergoing a multicentric phase I clinical trial as an anticancer agent, produces major analytical interference with commonly used creatinine analysis techniques. We confirm that this interference is caused by a metabolite rather than the parent compound and propose an alternative, interference-free method.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Grindey GB, Boder GB, Grossman CS, Howbert JJ, Poore G, Shaw WN, Todd GC, Worzalla JF (1987) Further development of diarylsulfonylureas as anticancer drugs. Proc Am Assoc Cancer Res 28: 309
Kroll MH, Roach NA, Poe B, Elin RJ (1987) Mechanism of interference with the Jaffé reaction for creatinine. Clin Chem 33: 1127
Taylor CW, Alberts DS, Ketchgam MA, Peng YM, Satterlee WG (1988) A phase I and pharmacokinetic study of LY186641 (LY). Abstract 226, Proceedings of the 24th Annual Meeting of the Am Soc Clin Oncology (ASCO), New Orleans, May 22–24, 1988
About this article
Cite this article
Bonnay, M.M., Recondo, G., Gouyette, A.J. et al. A new anticancer agent (LY186641) interferes with creatinine assay. Cancer Chemother. Pharmacol. 23, 119–120 (1989). https://doi.org/10.1007/BF00273530
- Clinical Trial
- Cancer Research
- Anticancer Agent
- Parent Compound